Canada Markets open in 2 hrs 27 mins

Marvel Biosciences Corp. (MRVL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.09500.0000 (0.00%)
At close: 03:44PM EDT
Full screen
Previous Close0.0950
Open0.1000
Bid0.0950 x N/A
Ask0.1000 x N/A
Day's Range0.0950 - 0.1000
52 Week Range0.0850 - 0.3900
Volume251,000
Avg. Volume13,317
Market Cap3.096M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Marvel Biosciences Announces Non-Brokered Private Placement

    Calgary, Alberta--(Newsfile Corp. - June 21, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce a proposed non-brokered private placement of units (the "Units") at a price of $0.10 per Unit for gross proceeds of up to $700,000 (the "Offering"). Each Unit will be comprised of one common share in the capital of the Company (a "Common Share") and ...

  • Newsfile

    Marvel Biosciences Initiates Formulation Development with Catalent

    Calgary, Alberta--(Newsfile Corp. - April 6, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that has initiated its pre-clinical oral formulation studies for its lead compound MB-204 with Catalent, Inc.Catalent, one of the world's largest contract research organizations, has begun development of novel solid ...

  • Newsfile

    Marvel Biosciences Announces Second Quarter 2022 Financial Results

    Calgary, Alberta--(Newsfile Corp. - March 30, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel") today announced its financial results for the second quarter ended January 31, 2022. For further information on these results, please see the Marvel Biosciences Corp. Condensed Interim Consolidated Financial Statements and Management Discussion & Analysis as filed on SEDAR."During the quarter ended January